The Quiet Crisis Behind America's Skilled Workforce

By Wesley Morris, Chief Executive Officer

A few years from now, the lab technician who runs your diagnostic panel, the bioprocessing operator who manufactures a life-saving therapy, and the quality control specialist who keeps a vaccine production line compliant may simply not show up. Not because they don’t exist but because the system meant to train and certify them broke down long before they got the chance.

That’s the certification crisis, and biotech is one of the places it’s hitting hardest.

The numbers don’t lie

More than 44 million U.S. jobs require some form of licensure or certification. Across the skilled trades broadly, the training pipeline is buckling: manufacturing alone reported over half a million unfilled job openings in early 2024, and the workers retiring out of these fields, 18.4 million of them by 2032, far outnumber the 13.8 million younger workers expected to replace them.

Biotechnology and life sciences manufacturing sit squarely inside this gap, and arguably face a sharper version of it. The industry has spent the last decade scaling rapidly, building new cell and gene therapy plants, expanding vaccine manufacturing capacity, and growing the diagnostics sector, while the talent pipeline for entry-level biomanufacturing and lab roles has not kept pace. Unlike many warehouse or assembly-line jobs, a biotech role can’t be learned purely on the floor. Technicians need to internalize Standard Operating Procedures, understand aseptic technique, and pass standardized, industry-recognized certification exams before they’re trusted anywhere near a production line or a clinical sample. That requirement, while necessary for safety and compliance, is exactly where the system is failing.

Here’s what surprised us most in our own research: this isn’t a demand problem. Interest in technical and applied science careers among young people has more than doubled since 2018. People want these jobs, and employers desperately want to fill them. The bottleneck is training capacity, specifically, the ability of biotech bootcamps, community college programs, and workforce training pipelines to get learners certified quickly and correctly.

And right now, they often can’t. First-attempt pass rates on key certification exams run as low as 10 to 30 percent across major technical fields. In biotech specifically, that delay isn’t just an inconvenience. It’s a production line short-staffed for two extra months, a lab running below capacity, a hiring pipeline that stalls right when demand is highest. Every failed attempt also costs employers real money: roughly $4,800 per worker stuck in limbo. Multiply that across an industry scaling as fast as biotech, and you start to see why economists estimate licensing and certification bottlenecks drain billions from the U.S. economy each year.

Why today’s tools fall short

Walk into most biotech training programs and you’ll find instructional materials that haven’t changed in a decade: dense SOP binders, PDF lecture notes, static slide decks describing lab protocols that learners are expected to absorb passively and then execute precisely. Learning management systems built for grade-point tracking, not for verified competency in a cleanroom or on a bioprocessing skid. None of it adapts to the learner in front of it. None of it tells an instructor, in real time, who has actually internalized the SOP and who is about to walk into a certification exam unprepared.

That gap between dense, technical training content and a learner’s actual readiness to demonstrate competency is the real crisis, and it’s especially costly in a field where the margin for error is measured in contamination risk and regulatory compliance, not just a failed quiz.

Closing the gap

This is the problem we started iTELL to solve.

Our platform, iTELL CTE, turns the instructional materials programs already have, including lab SOPs, lecture notes, technical manuals, into interactive, AI-tutored learning experiences. Instead of passively reading through a procedure, learners write short responses as they go and get real-time, personalized feedback grounded in how people actually learn and retain technical material. Instructors get a live dashboard showing exactly where each learner stands on the competencies tied to their certification exam, instead of finding out after a failed attempt or, worse, after a preventable error on the job.

It’s built on research, not guesswork. The underlying technology has been tested in university classrooms and is now being piloted directly in biotech and lab-skills training contexts: one pilot is using SOP-based intelligent texts to prepare laboratory skills learners for hands-on competency assessments, and another is supporting a biotechnology bootcamp where learners are preparing for an industry-recognized biotech certification exam. Both pilots are specifically designed to measure the outcome that matters most, first-attempt certification success, in the exact kind of program where the certification crisis bites hardest.

The stakes

This isn’t just about test scores. It’s about whether the next generation of lab technicians, bioprocessing operators, and quality control specialists can get certified fast enough to staff the facilities and fill the roles the biotech industry is already building. The interest is there. The SOPs and training materials already exist. What’s been missing is a way to turn that static content into training that actually prepares people to pass the first time.

That’s the gap we’re here to close.